文献速递头颈外科

喉鳞癌外泌体通过重塑神经微环境促进轴突生长

[Laryngeal squamous cell carcinoma-derived exosomes promote neuronal axonal growth by remodeling the neural microenvironment].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2026-01-01

该研究探讨喉鳞状细胞癌(LSCC)来源外泌体是否通过递送神经活性分子诱导轴突生长。TCGA-HNSC队列分析显示高神经密度为独立不良预后因素(HR=2.10,P=0.035),N0亚组HR=4.07(P=0.001)。体外实验证实LSCC外泌体促进PC12细胞神经突延伸及轴突生长基因上调,并可被GW4869逆转;靶向代谢组学显示外泌体富集谷氨酰胺和谷氨酸等12种神经递质及代谢物。

要点

  • 高神经密度是LSCC独立不良预后因素,N0亚组预警价值更显著。
  • LSCC外泌体可促进神经元样细胞轴突生长及分支。
  • 外泌体富集谷氨酰胺和谷氨酸等神经活性代谢物。

核心结论

  • 神经密度是喉鳞状细胞癌患者预后的潜在不良因素。
  • 喉癌来源外泌体可直接诱导神经元样细胞轴突生长,提示肿瘤细胞通过外泌体介导的远程信号主动重塑神经微环境。

研究设计与样本

  • 分析TCGA-HNSC喉癌队列临床数据,采用倾向性评分匹配(PSM)和Cox回归评估神经密度预后价值。
  • 收集2022—2026年烟台毓璜顶医院35对喉癌及癌旁组织标本验证神经形态学改变。
  • 提取人LSCC细胞系AMC-HN-8来源外泌体,与大鼠肾上腺嗜铬细胞瘤细胞PC12共培养,并使用GW4869进行逆转验证。
  • 采用免疫荧光和RT-qPCR检测神经突生长及轴突生长相关基因表达。
  • 采用靶向代谢组学对囊泡内神经活性代谢物进行绝对定量与通路富集分析。

主要发现

  • 经PSM校正后,高神经密度是LSCC患者不良预后因素(HR=2.10,P=0.035),在早期无淋巴结转移(N0期)亚组中预警价值显著(HR=4.07,P=0.001)。
  • 病理切片显示LSCC组织中神经标志物βIII-Tubulin和PGP9.5呈高表达(βIII-Tubulin:t=2.234,P<0.05;PGP9.5:t=2.575,P<0.05)。
  • 喉癌外泌体显著促进PC12细胞神经突延伸及分支(t=4.147,P<0.000 1),并上调GAP-43、NEFL、NEFM(GAP-43:t=3.698,P<0.05;NEFL:t=5.113,P<0.01;NEFM:t=5.263,P<0.01)。
  • 该效应可被外泌体分泌抑制剂GW4869逆转(t=3.535,P<0.001)。
  • 喉癌外泌体中特异性富集12种神经递质及代谢物,以谷氨酰胺(83.411 μmol/L,FC=1.88)和谷氨酸(18.461 μmol/L,FC=1.21)为核心,显著富集于「癌症中枢碳代谢」与「谷氨酸能突触」等信号网络。

临床怎么用

  • 神经密度可能作为LSCC预后评估的潜在指标,尤其在早期N0期患者中。
  • 外泌体介导的神经-肿瘤交互机制为LSCC神经浸润的干预提供潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Perineural invasion (PNI) is a critical determinant of poor prognosis in laryngeal squamous cell carcinoma (LSCC), but its underlying mechanisms remain unclear. This study aimed to investigate whether LSCC-derived exosomes induce axonal growth by delivering neuroactive molecules, thereby contributing to tumor perineural invasion. Methods: Clinical data from the laryngeal cancer cohort of The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma (TCGA-HNSC) dataset were analyzed. Propensity score matching (PSM) and Cox regression were used to evaluate the prognostic value of nerve density, and these findings were validated using 35 pairs of laryngeal cancer and adjacent normal tissue specimens collected at Yantai Yuhuangding Hospital between 2022 and 2026 to assess neural morphological changes. Exosomes were isolated from the human LSCC cell line AMC-HN-8, characterized by quality-control assays, and co-cultured with PC12 cells. A rescue experiment using GW4869, a specific inhibitor of neutral sphingomyelinase, was performed to confirm the exosome-dependent effect. Neurite outgrowth was evaluated by immunofluorescence, and the expression of axonal growth-related genes was measured by RT-qPCR. Targeted metabolomics was employed for the absolute quantification of neuroactive metabolites within the vesicles and for pathway enrichment analysis. Results: After PSM adjustment, high nerve density was identified as an independent poor prognostic factor in LSCC patients (HR=2.10, P=0.035), with particularly pronounced prognostic value in the early-stage node-negative (N0) subgroup (HR=4.07, P=0.001). Pathological sections showed high expression of the neural markers βIII-tubulin and PGP9.5 in LSCC tissues (βIII-tubulin: t=2.234, P<0.05; PGP9.5: t=2.575, P<0.05). Exosomes were successfully isolated from AMC-HN-8 cells and passed quality control. In vitro assays showed that LSCC-derived exosomes significantly promoted neurite extension and branching in PC12 cells (t=4.147, P<0.000 1) and upregulated core axonal growth genes, including GAP-43, NEFL, and NEFM (GAP-43: t=3.698, P<0.05; NEFL: t=5.113, P<0.01; NEFM: t=5.263, P<0.01); this effect was completely reversed by the exosome-release inhibitor GW4869 (t=3.535, P<0.001). Targeted metabolomics revealed a specific enrichment of 12 neurotransmitters and metabolites within LSCC exosomes, centered on glutamine (83.411 μmol/L, FC=1.88) and glutamate (18.461 μmol/L, FC=1.21), which were significantly enriched in signaling pathways such as "central carbon metabolism in cancer" and "glutamatergic synapse". Conclusion: Nerve density is a potential adverse prognostic factor in patients with LSCC. LSCC-derived exosomes can directly induce axonal growth in neuron-like cells, suggesting that tumor cells actively remodel the neural microenvironment and drive axonal growth through exosome-mediated long-range signaling. 目的: 神经浸润是喉鳞状细胞癌(LSCC)不良预后的关键因素,但其发生机制尚不明确。本研究旨在探讨喉癌来源外泌体是否通过递送神经活性分子诱导轴突生长,从而在肿瘤神经浸润中发挥调控作用。 方法: 利用癌症基因组图谱头颈鳞状细胞癌(TCGA-HNSC)喉癌队列临床数据,采用倾向性评分匹配(PSM)和Cox回归评估神经密度的预后价值,并结合2022—2026年烟台毓璜顶医院诊治的35对喉癌及癌旁临床样本验证神经组织形态学改变。提取人LSCC细胞系AMC-HN-8来源外泌体并质检,与大鼠肾上腺嗜铬细胞瘤细胞PC12共培养,并使用中性鞘磷脂酶特异性抑制剂4′,4′′-双-2-咪唑啉-2-基对苯二丙烯酰苯胺二盐酸盐(GW4869)进行逆转验证,通过免疫荧光及实时荧光定量反转录检测神经突生长情况。采用靶向代谢组学对囊泡内神经活性代谢物进行绝对定量与通路富集分析。 结果: 临床分析表明,经PSM校正后,高神经密度是LSCC患者的不良预后因素(HR=2.10,P=0.035),且在早期无淋巴结转移(N0期)亚组中预警价值尤为显著(HR=4.07,P=0.001)。病理切片显示LSCC组织中神经标志物βIII-Tubulin、PGP9.5呈高表达(βIII-Tubulin:t=2.234,P<0.05;PGP9.5:t=2.575,P<0.05)。成功从AMC-HN-8细胞中提取出外泌体并质检合格。细胞试验显示,喉癌外泌体显著促进PC12细胞神经突延伸及分支能力(t=4.147,P<0.000 1),并显著上调GAP-43、NEFL、NEFM等轴突生长核心基因(GAP-43:t=3.698,P<0.05;NEFL:t=5.113,P<0.01;NEFM:t=5.263,P<0.01),该效应可被外泌体分泌抑制剂逆转(t=3.535,P<0.001)。靶向组学定量揭示,喉癌外泌体中特异性地富集了以谷氨酰胺(83.411 μmol/L,FC=1.88)和谷氨酸(18.461 μmol/L,FC=1.21)为核心的12种神经递质及代谢物,显著富集于“癌症中枢碳代谢”与“谷氨酸能突触”等信号网络。 结论: 神经密度是喉癌患者预后的潜在不良因素。喉癌来源的外泌体能够直接诱导神经元样细胞的轴突生长,提示肿瘤细胞可能通过外泌体介导的远程信号传递,主动调控神经微环境,驱动神经轴突生长。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu WC, Ren C, Tao CX, et al. [Laryngeal squamous cell carcinoma-derived exosomes promote neuronal axonal growth by remodeling the neural microenvironment]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2026. PMID: 42706064. doi:10.3760/cma.j.cn115330-20260120-00044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。